Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 16/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30008533 | 0.93 | BDKRB1 (0.48) | BDKRB1S1PR1MAPK14SMYD3 | |
| SCHEMBL21270572 | 0.90 | BDKRB1 (0.57) | BDKRB1MAPK14SMYD3 | |
| SCHEMBL21270573 | 0.90 | BDKRB1 (0.57) | BDKRB1MAPK14SMYD3 | |
| SCHEMBL21178816 | 0.90 | BDKRB1 (0.62) | BDKRB1 | |
| SCHEMBL21270863 | 0.89 | BDKRB1 (0.56) | BDKRB1MAPK14SMYD3 | |
| SCHEMBL21270861 | 0.89 | BDKRB1 (0.56) | BDKRB1MAPK14SMYD3 | |
| SCHEMBL21284747 | 0.89 | BDKRB1 (0.51) | BDKRB1MAPK14SMYD3 | |
| SCHEMBL21284715 | 0.88 | S1PR1 (0.45) | BDKRB1S1PR1 | |
| SCHEMBL21284638 | 0.87 | BDKRB1 (0.49) | BDKRB1S1PR1 | |
| SCHEMBL21284635 | 0.86 | ALDH1A1 (0.45) | BDKRB1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740481-B9 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-10-23 | — | — | EP | claimed |
| EP-3740481-B1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-06-26 | — | — | EP | claimed |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12065436-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11472796-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10836755-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885S1PR1 916/4885MAPK14 2299/4885 |
| US-10836755-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885S1PR1 916/4885MAPK14 2299/4885 |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885S1PR1 916/4885MAPK14 2299/4885 |
| US-12065436-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885S1PR1 916/4885MAPK14 2299/4885 |
| US-11472796-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885S1PR1 916/4885MAPK14 2299/4885 |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885S1PR1 916/4885MAPK14 2299/4885 |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885S1PR1 916/4885MAPK14 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.